Serotonin Plasma Membrane Transport Proteins - Metabolism
Research News and Information

Sunday, November 22, 2009

MDMA pretreatment leads to mild chronic unpredictable stress-induced impairments in spatial learning.

29 Sep 2009 3,4-Methylenedioxymethamphetamine (MDMA) is a drug of abuse worldwide and a selective serotonin (5-HT) neurotoxin. An important factor in the risk of drug abuse and relapse is stress. Although multiple parallels exist between MDMA abuse and stress, ... Read more...

1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.

22 Sep 2009 Sequential structural modifications of the aryloxypropanamine template (e.g., atomoxetine, 2) led to a novel series of 1-(3-amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors (NRIs). ... Read more...

Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.

14 Sep 2009 Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder, caused by a polyglutamine expansion in the huntingtin protein (htt). Increasing evidence suggests that transglutaminase (TGase) plays a critical role in the ... Read more...

Latest indexed articles for 'Serotonin Plasma Membrane Transport Proteins - Metabolism'

These are the very latest articles for this heading:

• MDMA pretreatment leads to mild chronic unpredictable stress-induced impairments in spatial learning. 29 Sep 2009
• 1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors. 22 Sep 2009
• Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease. 14 Sep 2009
• The human serotonin transporter gene explains why some populations are more optimistic? 30 Aug 2009
• In vivo characterization of a series of 18F-diaryl sulfides (18F-2-(2'-((dimethylamino)methyl)-4'-(fluoroalkoxy)phenylthio)benzenamine) for PET imaging of the serotonin transporter. 16 Aug 2009
• Serotonin transporter availability in the amygdala and bed nucleus of the stria terminalis predicts anxious temperament and brain glucose metabolic activity. 10 Aug 2009
• Expression of placental serotonin transporter and 5-HT 2A receptor in normal and gestational diabetes mellitus pregnancies. 30 Jul 2009
• 5-HTTLPR modulates antidepressant efficacy in depressed women. 30 Jul 2009
• Sex influences the effect of a lifelong increase in serotonin transporter function on cerebral metabolism. 30 Jul 2009
• Corticotropin-releasing factor, serotonin, and sex: keys to the castle of depressive illness. 30 Jul 2009
• Altered brain serotonin transporter and associated glucose metabolism in Alzheimer disease. 15 Jul 2009
• An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant. 14 Jul 2009
• Synthesis and biological characterization of (3R,4R)-4-(2-(benzhydryloxy)ethyl)-1-((R)-2-hydroxy-2-phenylethyl)-piperidin-3-ol and its stereoisomers for activity toward monoamine transporters. 29 Jun 2009
• Neural connectivity as an intermediate phenotype: brain networks under genetic control. 29 Jun 2009
• Reported childhood abuse is associated with low serotonin transporter binding in vivo in major depressive disorder. 29 Jun 2009
• Two allelic isoforms of the serotonin transporter from Schistosoma mansoni display electrogenic transport and high selectivity for serotonin. 19 Jun 2009
• Regulation of serotonin transporter activity by adenosine in intestinal epithelial cells. 15 Jun 2009
• Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin. 12 Jun 2009
• An extended study of dimeric phenyl tropanes. 8 Jun 2009
• Serotonin transporter binding and genotype in the nonhuman primate brain using [C-11]DASB PET. 4 Jun 2009

See a longer list of these articles.

Technical information about 'Serotonin Plasma Membrane Transport Proteins'

Definition: Sodium chloride-dependent neurotransmitter symporters located primarily on the PLASMA MEMBRANE of serotonergic neurons. They are different than SEROTONIN RECEPTORS, which signal cellular responses to SEROTONIN. They remove SEROTONIN from the EXTRACELLULAR SPACE by high affinity reuptake into PRESYNAPTIC TERMINALS. Regulates signal amplitude and duration at serotonergic synapses and is the site of action of the SEROTONIN UPTAKE INHIBITORS.

Registry Number: 0

Descriptor UI: D050486

Alternative terms: Serotonin Plasma Membrane Transport Proteins; 5HT Transporter; Neurotransmitter Transport Proteins, Serotonin-Specific; Neurotransmitter Transport Proteins, Serotonin Specific; Sodium-Dependent Serotonin Transporter; Serotonin Transporter, Sodium-Dependent; Sodium Dependent Serotonin Transporter; Transporter, Sodium-Dependent Serotonin; Serotonin Plasma Membrane Transporter Proteins; Serotonin Transporter; Transporter, Serotonin; SERT Proteins; 5-Hydroxytryptamine Plasma Membrane Transport Protein; 5 Hydroxytryptamine Plasma Membrane Transport Protein; Neurotransmitter Transporters, Serotonin-Specific; Neurotransmitter Transporters, Serotonin Specific; Serotonin-Specific Neurotransmitter Transporters; Transporters, Serotonin-Specific Neurotransmitter; Serotonectin; Serotonin Transporter, Platelets; Platelets Serotonin Transporter; Transporter, Platelets Serotonin; Platelet Serotonin Transporter; Serotonin Transporter, Platelet; Transporter, Platelet Serotonin;

Related Mesh Headings: Receptors, Serotonin;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Tree Number: D12.776.157.530.450.625.311; D12.776.157.530.562.374.875; D12.776.543.585.450.625.374; D12.776.543.585.562.374.875;

History Note: 2006(1992)